ZA201407551B - Methods of treating cancer using aurora kinase inhibitors - Google Patents

Methods of treating cancer using aurora kinase inhibitors

Info

Publication number
ZA201407551B
ZA201407551B ZA2014/07551A ZA201407551A ZA201407551B ZA 201407551 B ZA201407551 B ZA 201407551B ZA 2014/07551 A ZA2014/07551 A ZA 2014/07551A ZA 201407551 A ZA201407551 A ZA 201407551A ZA 201407551 B ZA201407551 B ZA 201407551B
Authority
ZA
South Africa
Prior art keywords
methods
treating cancer
kinase inhibitors
aurora kinase
aurora
Prior art date
Application number
ZA2014/07551A
Other languages
English (en)
Inventor
Chakravarty Arijit
A Ecsedy Jeffrey
N Le Kha
Chyi Shyu Wen
W Kleinfield Robert
Venkatakrishnan Karthik
Original Assignee
Millennium Pharmaceuticals Inc A Corp Organised And Existing Under The Laws Of The State Of Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc A Corp Organised And Existing Under The Laws Of The State Of Delaware filed Critical Millennium Pharmaceuticals Inc A Corp Organised And Existing Under The Laws Of The State Of Delaware
Publication of ZA201407551B publication Critical patent/ZA201407551B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2014/07551A 2012-03-20 2014-10-17 Methods of treating cancer using aurora kinase inhibitors ZA201407551B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613258P 2012-03-20 2012-03-20
PCT/US2013/032962 WO2013142491A1 (en) 2012-03-20 2013-03-19 Methods of treating cancer using aurora kinase inhibitors

Publications (1)

Publication Number Publication Date
ZA201407551B true ZA201407551B (en) 2019-01-30

Family

ID=48048255

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/07551A ZA201407551B (en) 2012-03-20 2014-10-17 Methods of treating cancer using aurora kinase inhibitors

Country Status (24)

Country Link
US (2) US20130303519A1 (enExample)
EP (1) EP2827855B1 (enExample)
JP (1) JP6373252B2 (enExample)
KR (1) KR102128866B1 (enExample)
CN (1) CN104271129A (enExample)
AU (1) AU2013235275B2 (enExample)
CA (1) CA2868024A1 (enExample)
EA (1) EA036434B1 (enExample)
ES (1) ES2746946T3 (enExample)
GE (1) GEP20186900B (enExample)
IL (1) IL234686B (enExample)
IN (1) IN2014DN08477A (enExample)
JO (1) JO3630B1 (enExample)
MA (1) MA37438A1 (enExample)
MX (1) MX358411B (enExample)
MY (1) MY175225A (enExample)
NZ (1) NZ700744A (enExample)
PH (1) PH12014502109A1 (enExample)
SG (2) SG10201607741RA (enExample)
TN (1) TN2014000387A1 (enExample)
TW (1) TWI649082B (enExample)
UA (1) UA117455C2 (enExample)
WO (1) WO2013142491A1 (enExample)
ZA (1) ZA201407551B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
JP2018502089A (ja) * 2014-12-23 2018-01-25 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｒａｆ阻害剤及びａｕｒｏｒａキナーゼ阻害剤の組み合わせ
US20190194750A1 (en) * 2015-07-02 2019-06-27 Millennium Pharmaceuticals, Inc. Biomarkers of response to selective inhibitors of aurora a kinase
CN110833544B (zh) * 2018-08-17 2022-08-09 深圳微芯生物科技股份有限公司 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
NL8000715A (nl) 1979-02-07 1980-08-11 Hoffmann La Roche Pyrimido-2-benzazepinen, werkwijzen ter bereiding ervan, alsmede farmaceutische preparaten, die deze pyrimido-2- benzazepinen bevatten.
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
AU723860B2 (en) 1996-03-08 2000-09-07 Astrazeneca Ab Azolobenzazepine derivatives as neurologically active agents
JP2001507349A (ja) 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
TR200000808T2 (tr) 1997-09-29 2000-08-21 Meiji Seika Kaisha, Ltd. Triscyklik triyazolobenzazepin türevler, bunları üretme süreci ve anti alerjik.
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
EP1318814B1 (en) 2000-09-15 2007-05-30 Vertex Pharmaceuticals Incorporated Triazole compounds useful as protein kinase inhibitors
US7625913B2 (en) 2000-12-21 2009-12-01 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
JP4364637B2 (ja) 2001-08-09 2009-11-18 アクテリオン ファーマシューティカルズ リミテッド 新規なベンゾ縮合へテロ環化合物
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
AU2005213472A1 (en) 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
NZ551370A (en) 2004-05-14 2009-08-28 Millennium Pharm Inc Compounds and methods for inhibiting mitotic progression by inhibiting of aurora kinase
JP2008520713A (ja) 2004-11-17 2008-06-19 ミイカナ セラピューティクス インコーポレイテッド キナーゼ阻害剤
WO2006070198A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
ES2408318T3 (es) 2005-12-23 2013-06-20 Glaxosmithkline Llc Inhibidores de azaindol de las cinasas Aurora
US8865212B2 (en) 2006-01-16 2014-10-21 Jubilant Generics Limited Stable pharmaceutical formulation of an acid labile compound and process for preparing the same
CL2007000667A1 (es) 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
DE102006012301A1 (de) 2006-03-15 2007-09-20 Cemag-Anlagenbau-Dessau Gmbh Herstellung von Zementklinker
EP2054413A2 (en) 2006-08-09 2009-05-06 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CA2668267A1 (en) 2006-10-31 2008-05-08 Achillion Pharmaceuticals, Inc. Elvucitabine pharmaceutical compositions
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
PE20081891A1 (es) 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
WO2009158687A1 (en) 2008-06-26 2009-12-30 Anterios, Inc. Dermal delivery
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CA2788774A1 (en) * 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors

Also Published As

Publication number Publication date
NZ700744A (en) 2016-09-30
CA2868024A1 (en) 2013-09-26
JP6373252B2 (ja) 2018-08-15
EP2827855B1 (en) 2019-06-26
UA117455C2 (uk) 2018-08-10
MY175225A (en) 2020-06-16
IN2014DN08477A (enExample) 2015-05-08
AU2013235275B2 (en) 2017-12-07
HK1206253A1 (en) 2016-01-08
TWI649082B (zh) 2019-02-01
SG11201405621UA (en) 2014-10-30
MA37438A1 (fr) 2016-05-31
ES2746946T3 (es) 2020-03-09
JO3630B1 (ar) 2020-08-27
KR102128866B1 (ko) 2020-07-01
JP2015510945A (ja) 2015-04-13
MX358411B (es) 2018-08-20
GEP20186900B (en) 2018-10-10
KR20140144215A (ko) 2014-12-18
TW201343169A (zh) 2013-11-01
US20130303519A1 (en) 2013-11-14
AU2013235275A1 (en) 2014-10-23
MX2014011324A (es) 2014-12-05
US20160193224A1 (en) 2016-07-07
EA201491727A1 (ru) 2015-01-30
IL234686A0 (en) 2014-11-30
SG10201607741RA (en) 2016-11-29
PH12014502109A1 (en) 2014-12-10
EA036434B1 (ru) 2020-11-10
EP2827855A1 (en) 2015-01-28
CN104271129A (zh) 2015-01-07
IL234686B (en) 2020-01-30
TN2014000387A1 (en) 2015-12-21
WO2013142491A1 (en) 2013-09-26
US10213436B2 (en) 2019-02-26

Similar Documents

Publication Publication Date Title
IL288181A (en) Cancer treatment methods
IL274318A (en) Cancer treatment with rapamycin target site kinase inhibitors
ZA201402771B (en) Treatment of cancer with tor kinase inhibitors
IL237791A0 (en) A method for treating cancer
IL234639B (en) Cancer treatment with rapamycin target site kinase inhibitors
ZA201406706B (en) Treatment of cancer with tor kinase inhibitors
IL234641B (en) Cancer treatment with rapamycin target site kinase inhibitors
EP2895206A4 (en) METHOD FOR TREATING CARCINOMA
ZA201503105B (en) Treatment of prostate cancer with tor kinase inhibitors
PL2817286T3 (pl) Inhibitory kinazy do leczenia raka
ZA201407551B (en) Methods of treating cancer using aurora kinase inhibitors
IL237229A0 (en) Methods of treating cancer using lipoplatin
ZA201502294B (en) Treatment of cancer with tor kinase inhibitors